Cidara Therapeutics reports Q3 EPS ($3.10), consensus ($1.33)

Reports Q3 revenue $0, consensus $0. Cash, cash equivalents, restricted cash and available-for-sale investments totaled $476.5M as of September 30, 2025. “With our Phase 3 ANCHOR study now over 50 percent enrolled, we expect to achieve target enrollment of 6,000 participants by December 2025 and thereby advance CD388 as a potential universal preventative for people at increased risk of complications from influenza as well as those seeking alternatives to flu vaccines,” said Jeffrey Stein, president and CEO of Cidara. “Based on constructive feedback from the FDA, the ANCHOR study population has been expanded to include generally healthy adults over the age of 65 in addition to individuals with certain comorbidities or compromised immune status. This change more than doubles the target population potentially eligible to receive CD388. Our successful financing this summer has provided us with a strong balance sheet that we expect to be sufficient to fully fund our Phase 3 development program through completion.”